These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 28584788)
1. Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis. Kwon YS Chonnam Med J; 2017 May; 53(2):103-109. PubMed ID: 28584788 [TBL] [Abstract][Full Text] [Related]
2. Synthetic investigational new drugs for the treatment of tuberculosis. Kwon YS; Koh WJ Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
5. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149 [TBL] [Abstract][Full Text] [Related]
6. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Kwon YS; Jeong BH; Koh WJ Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169 [TBL] [Abstract][Full Text] [Related]
7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
8. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722 [TBL] [Abstract][Full Text] [Related]
9. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid. Pecora F; Dal Canto G; Veronese P; Esposito S Microorganisms; 2021 May; 9(5):. PubMed ID: 34067732 [TBL] [Abstract][Full Text] [Related]
11. Bedaquiline and delamanid in tuberculosis. Esposito S; Bianchini S; Blasi F Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803 [TBL] [Abstract][Full Text] [Related]
12. Pretomanid development and its clinical roles in treating tuberculosis. Fekadu G; Tolossa T; Turi E; Bekele F; Fetensa G J Glob Antimicrob Resist; 2022 Dec; 31():175-184. PubMed ID: 36087906 [TBL] [Abstract][Full Text] [Related]
13. Tuberculosis: clinical trials and new drug regimens. Kwon YS; Jeong BH; Koh WJ Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239 [TBL] [Abstract][Full Text] [Related]
14. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
16. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. D'Ambrosio L; Centis R; Tiberi S; Tadolini M; Dalcolmo M; Rendon A; Esposito S; Migliori GB J Thorac Dis; 2017 Jul; 9(7):2093-2101. PubMed ID: 28840010 [TBL] [Abstract][Full Text] [Related]
17. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Blair HA; Scott LJ Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020 [TBL] [Abstract][Full Text] [Related]
18. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
19. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]